The group describes the clinical gaps that prompted development of bispecifics and summarizes the currently available agents for relapsed/refractory disease. Stay ahead of policy, cost, and ...

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...

During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

Good day, everyone, and welcome to the Syndax Conference Call to Discuss the FDA approval of Revuforj in Relapsed/Refractory NPM1 Mutated AML. Today's call is being recorded. [Operator Instructions] ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...

Real world outcomes of venetoclax combined with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: Insights from a tertiary care centre in Pakistan. This is an ASCO Meeting ...